Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]
Biomarkers for personalised cancer treatment
This article reviews all the biomarkers that have been discovered [...]
Cancer vaccine ilixadencel triggers strong immune response in newly diagnosed kidney cancer tumours
Results from the first phase of a phase 1/2 clinical [...]
Tivozanib given the green light by European regulators for first-line treatment of advanced kidney cancer
Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine [...]
England’s first high-energy proton beam therapy machine installed at the Christie Centre, Manchester
England's first high-energy proton beam therapy machine was installed at the [...]
World Kidney Cancer Day raises awareness of the five key signs of kidney cancer
This article in the Express highlights the 5 key signs [...]
First ever World Kidney Cancer Day highlights the risks associated with kidney cancer – TODAY
Kidney cancer is a serious and deadly disease that affects [...]
New treatment options for papillary renal cell carcinoma
This video interview summarises treatments in development for papillary renal [...]
Cabozantinib significantly improves progression free survival compared to sunitinib as first-line treatment for advanced kidney cancer
Review by a blinded independent radiology review committee (IRC) has [...]
Tivozanib plus nivolumab combination enters phase II clinical trials
The phase I dose-escalation phase of the TiNivo trial, which [...]
